Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899229 | 0.78 | CRHR1 (0.44) | CRHR1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3903868 | 0.76 | DRD2 (0.37) | — | |
| SCHEMBL3907847 | 0.76 | — | — | |
| SCHEMBL3908307 | 0.74 | MEN1 (0.31) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Trifluoroacetic Acid SCHEMBL3898358 | 0.73 | CRHR1 (0.49) | CRHR1KMONPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3899529 | 0.72 | ALDH1A1 (0.40) | TSHRL3MBTL1POLBHDAC1 | |
| SCHEMBL3895344 | 0.72 | EGLN3 (0.31) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5946285 | 0.70 | RECQL (0.54) | CRHR1KMONPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3899606 | 0.70 | GABRP (0.31) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22362318 | 0.69 | PLG (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799639-B1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS SA (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-7538128-B2 | Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7524844-B2 | Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-04-28 | — | — | US | disclosed |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-11 | — | — | US | disclosed |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-04 | — | — | US | disclosed |
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | disclosed |
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACETUCALS, S.A. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | DPP4, DPP3, DPP7 | CRHR1 1878/4885KMO 3786/4885NPC1 942/4885 |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | CRHR1 1806/4885KMO 3396/4885NPC1 1400/4885 |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | CRHR1 1806/4885KMO 3396/4885NPC1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.